PIPE-307

We recently completed a randomized, double-blind, placebo-controlled, safety and tolerability, pharmacokinetic, single and multiple-ascending dose Phase 1 study of PIPE-307 in healthy volunteers enrolled at a single center in Australia.

Visit ClinicalTrials.gov

In the second half of 2021 we completed a Phase 1, single-center, open-label, adaptive-design study to investigate the occupancy of brain M1R after a single oral dose of PIPE-307 in healthy volunteers by positron emission tomography (PET) using the radioligand [11C] PIPE-307.

Visit ClinicalTrials.gov

PIPE-505

In 2021 we completed a multi-center, randomized, double-blind, placebo-controlled Phase 1/2a clinical trial of PIPE-505 in patients with sensorineural hearing loss associated with speech-in-noise impairment (i.e., difficulty interpreting speech in the presence of background noise). Clinical responses were assessed at one, two, and three months following administration of PIPE-505 via an outpatient single intra-tympanic injection.

Visit ClinicalTrials.gov